Rapid Micro Biosystems (RPID) Common Equity (2020 - 2026)

Rapid Micro Biosystems has disclosed Common Equity across 7 years of filings, most recently posting $20.4 million for Q1 2026.

• Common Equity for Q1 2026 came in at $20.4 million, down 68.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.4 million (down 68.85% YoY), and the FY2025 annual result was $33.2 million, down 55.93% from the prior year.
• Common Equity came in at $20.4 million for Q1 2026 at Rapid Micro Biosystems, down from $33.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $207.1 million in Q1 2022 to a low of $20.4 million in Q1 2026.
• The 5-year median for Common Equity is $105.9 million (2024), against an average of $109.5 million.
• Across the five-year window, Common Equity surged 237.09% in 2022 and plunged 68.85% in 2026, its largest moves.
• Rapid Micro Biosystems' Common Equity stood at $164.2 million in 2022, then dropped by 28.13% to $118.0 million in 2023, then plunged by 36.14% to $75.4 million in 2024, then sank by 55.93% to $33.2 million in 2025, then slumped by 38.57% to $20.4 million in 2026.
• The last three Common Equity figures came in at $20.4 million (Q1 2026), $33.2 million (Q4 2025), and $44.3 million (Q3 2025), per Business Quant data.